Jejunoileal vs Gastric GIST in the Era of Imatinib.

Plain-language summary

This observational study aimed to compare gastrointestinal stromal tumors (GIST) arising in different parts of the digestive tract (small bowel versus stomach) in the era of Imatinib. Patients with a histological and immunohistochemical profile consistent with GIST were included. The study had no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Hospital Universitario Virgen de la Arrixaca

Start date

11/1/2016

Estimated completion

1/31/2017

Countries

Spain

Related genes

Locations

• Murcia, Spain

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Any kind of primary mesenchymal tumor of the gastrointestinal tract with a histomorphological and immunohistochemical (CD117 (+) and/or DOG1 (+)) profile consistent with GIST.

Exclusion Criteria:

\-